Cited 37 times in
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김한상 | - |
dc.date.accessioned | 2022-05-09T16:53:35Z | - |
dc.date.available | 2022-05-09T16:53:35Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188267 | - |
dc.description.abstract | Background & aims: Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III trial. Further evaluation is necessary to investigate the safety and efficacy of Ate/Bev in real settings. Methods: This was a multicentre retrospective analysis. Between May 2020 and February 2021, 138 patients received Ate/Bev as first-line treatment for advanced HCC from 11 institutions. We excluded patients with Child-Pugh B or C and BCLC D stage, and the remaining 121 patients were included in this analysis. Results: According to RECIST 1.1, the objective response and disease control rates were 24.0% and 76.0%. The median follow-up duration was 5.9 months (95% confidence interval [CI], 5.4-6.4), the median progression-free survival (PFS) was 6.5 months (95% CI, 4.1-9.0), and median overall survival (OS) was not reached (95% CI, not available). The most frequent grade 3-4 adverse event was aspartate aminotransferase elevation (10.7%). In the multivariate analyses, AFP increase (P = .037), baseline neutrophil-to-lymphocyte ratio (NLR) ≥ 5 (P = .023), and best response to stable disease or progressive disease (P = .019) were significantly associated with worse PFS. Macrovascular invasion (P = .048) and baseline NLR ≥5 (P < .001) were significantly associated with worse OS. Conclusions: Ate/Bev showed real-life efficacy and safety in Korean patients with advanced HCC, in line with results from phase III trial. Considering unfavourable survival outcomes of Ate/Bev in patients with elevated NLR, careful assessment of treatment response needs to be performed in this group. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Bevacizumab / adverse effects | - |
dc.subject.MESH | Carcinoma, Hepatocellular* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jaekyung Cheon | - |
dc.contributor.googleauthor | Changhoon Yoo | - |
dc.contributor.googleauthor | Jung Yong Hong | - |
dc.contributor.googleauthor | Han Sang Kim | - |
dc.contributor.googleauthor | Dae-Won Lee | - |
dc.contributor.googleauthor | Myung Ah Lee | - |
dc.contributor.googleauthor | Jin Won Kim | - |
dc.contributor.googleauthor | Ilhwan Kim | - |
dc.contributor.googleauthor | Sang-Bo Oh | - |
dc.contributor.googleauthor | Jun-Eul Hwang | - |
dc.contributor.googleauthor | Hong Jae Chon | - |
dc.contributor.googleauthor | Ho Yeong Lim | - |
dc.identifier.doi | 10.1111/liv.15102 | - |
dc.contributor.localId | A01098 | - |
dc.relation.journalcode | J02171 | - |
dc.identifier.eissn | 1478-3231 | - |
dc.identifier.pmid | 34792284 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/liv.15102 | - |
dc.subject.keyword | atezolizumab | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | neutrophil-to-lymphocyte ratio | - |
dc.contributor.alternativeName | Kim, Han Sang | - |
dc.contributor.affiliatedAuthor | 김한상 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 674 | - |
dc.citation.endPage | 681 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, Vol.42(3) : 674-681, 2022-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.